Refine by
Hepatitis B Virus Articles & Analysis
28 news found
Creative Diagnostics, a leading manufacturer and supplier of antibodies, antigens and assay kits, has announced the expansion of its Hepatitis B research portfolio with a comprehensive range of sensitive and specific Hepatitis B Virus Surface Antigen L-proteins. ...
Amerigo Scientific, as a distributor focused on providing critical products and services to biomedical and life science communities, recently rolled out their cutting-edge real-time PCR kits for Hepatitis A virus (HAV) research. The new kits offer researchers excellent accuracy, sensitivity, and convenience in studying and analyzing HAV samples. Hepatitis A is a highly contagious viral ...
Creative Diagnostics, a global leader in offering raw materials, antibodies, and reagents for the bio-technology industry, announced the launch of Monkeypox Virus Antigens and Antibodies to support scientists focused on the research of monkeypox virus. These products are only intended for research use, not for diagnostic or clinical purposes. Monkeypox is a rare disease caused by infection with ...
” “We are pleased to be able to maintain and increase our support of VBI’s commercialization and pipeline development efforts, and we look forward to continuing to work with the VBI team in their mission to address significant unmet needs in infectious disease and oncology,” said Anup Arora, Founding Managing Director and Chief Investment Officer of K2HV. About ...
” PreHevbri was approved by the European Commission (EC) and the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA) in the second quarter of 2022 for active immunization against infection caused by all known subtypes of the hepatitis B virus (HBV) in adults. About Hepatitis B ...
CD BioGlyco, a biotechnology company specialized in the field of glycobiology, has developed a series of advanced vaccine development platforms by integrating various advanced technologies to promote the development of glycol-based vaccines. Hepatitis C virus (HCV) envelope glycoproteins E1 and E2 are critical in viral attachment and cell fusion, and investigation of these proteins may provide ...
Dillman will be responsible for leading VBI’s commercial strategy, sales, and sales operations, including the commercialization of VBI’s 3-Antigen Hepatitis B Vaccine (HBV), PreHevbrio™ [Hepatitis B Vaccine (Recombinant)]. ...
About VBI’s 3-Antigen HBV Vaccine VBI’s hepatitis B vaccine is the only 3-antigen hepatitis B vaccine, comprised of the three surface antigens of the hepatitis B virus – S, pre-S1, and pre-S2. ...
(Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) has granted marketing authorisation for PreHevbri™ [Hepatitis B vaccine (recombinant, adsorbed)] for active immunisation against ...
An estimated 900,000 people die each year from complications of chronic HBV such as liver decompensation, cirrhosis, and hepatocellular carcinoma. About PreHevbrio™ [Hepatitis B Vaccine (Recombinant)] / PreHevbri™ [Hepatitis B vaccine (recombinant, adsorbed)] VBI’s hepatitis B ...
The Company has two commercial products, HEPLISAV-B® vaccine [Hepatitis B Vaccine (Recombinant), Adjuvanted], which is approved in the U.S. and the European Union for the prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older, and CpG 1018 ...
The Company has two commercial products, HEPLISAV-B® vaccine [Hepatitis B Vaccine (Recombinant), Adjuvanted], which is approved in the U.S. and the European Union for the prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older, and CpG 1018 ...
Continued the design, synthesis and testing of new compounds under its Hepatitis B program. SARS-CoV-2 During the quarter ended 31 March 2022, the Company announced new data that confirms and extends previous findings that BIT225 had demonstrated substantial and clinically meaningful efficacy against SARS-CoV-2 in a series of animal and cell-based studies ...
The Company's first commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the U.S. and the European Union for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. ...
The Company's first commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the U.S. and the European Union for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. ...
The Company's first commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the U.S. and the European Union for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. ...
The Company's first commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the U.S. and the European Union for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. ...
Bristol-Myers Squibb K.K. today announced that Japan’s Ministry of Health, Labour and Welfare has approved Abecma (idecabtagene vicleucel), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell immunotherapy, for the treatment of adult patients with relapsed or refractory (R/R) multiple myeloma, who have received at least three prior therapies, including an ...
In the prime dose, ‘ChAdOx1’ refers to the viral vector used in the vaccine to deliver the antigens. It is a virus which causes a common cold in chimpanzees, but it has been modified so that it can no longer cause disease. ...
Dynavax expects year over year revenue growth for HEPLISAV-B and CpG 1018 adjuvant to drive continued profitability in 2022 Strong financial position supports investment in long-term growth drivers including pipeline expansion Initiation of Phase 1 clinical trial of shingles vaccine candidate, adjuvanted with CpG 1018, with data expected year end 2022 Dynavax ...